Failure of losartan to control blood pressure in scleroderma renal crisis

Lancet

Volumn 349, Issue 9052, 1997, Pages 620-

  Caskey, F J ^b   Thacker, E J ^b   Johnston, P A ^b   Barnes, J N ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LABETALOL; LISINOPRIL; LOSARTAN; METHYLDOPA; NIFEDIPINE; NITRATE; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINOPATHY; SCLERODERMA; TREATMENT FAILURE; VOMITING;

EID: 0343554031     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61568-1     Document Type: Article

References (4)

1. Steen VD. Renal involvement in systemic sclerosis. Clin Dermatol 1994; 12: 253-58.
2. Steen VD, Costantino JP, Shapiro AP, Medsger TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-57.
3. Donohoe JF. Scleroderma and the kidney. Kidney Int 1992; 41: 462-77.
4. Shand BI, Gilchrist NL, Nicholls MG, Bailey RR. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233-35.